拉莫三嗪联合丙戊酸钠对初诊癫痫的临床疗效评价

Clinical Efficacy of Lamotrigine Combined with Sodium Valproate in the Treatment of Newly Diagnosed Epilepsy

目的:探讨拉莫三嗪联合丙戊酸钠治疗初诊癫痫的临床效果。方法:选取本院2016年3月-2020年12月初诊癫痫患者60例,采用随机数字表法分为对照组(n=30)和观察组(n=30)。对照组给予丙戊酸钠治疗,观察组给予拉莫三嗪联合丙戊酸钠治疗。两组均持续治疗6个月,观察两组临床治疗效果、治疗前后细胞因子肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-Iβ(interleukin-Iβ,IL-Iβ)、白细胞介素-6(interleukin-6,IL-6)水平及不良反应的发生情况。结果:观察组治疗总有效率为96.67%,高于对照组的73.33%,差异有统计学意义(P<0.05)。治疗前,两组间血清TNF-α、IL-Iβ及IL-6水平比较,差异均无统计学意义(P>0.05);治疗后,两组血清TNF-α、IL-Iβ、IL-6水平均低于治疗前,且观察组各细胞因子水平均低于对照组,差异均有统计学意义(P<0.05)。两组治疗期间的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:拉莫三嗪联合丙戊酸钠治疗初诊癫痫临床效果确切,安全性较好,在临床治疗中值得借鉴。

Objective:To evaluate the clinical efficacy of Lamotrigine combined with Sodium Valproate in the treatment of newly diagnosed epilepsy.Method:A total of 60 newly diagnosed epilepsy patients in our hospital from March 2016 to December 2020 were selected and randomly divided into control group(n=30)and observation group(n=30).The control group was treated with Sodium Valproate,and the observation group was treated with Lamotrigine combined with Sodium Valproate.Both groups were treated continuously for 6 months.Clinical efficacy,cytokine levels[tumor necrosis factor-α(TNF-α),interleukin-Iβ(IL-Iβ),interleukin-6(IL-6)]and adverse reactions of the two groups were observed.Result:The total effective rate of the observation group was 96.67%,which was higher than 73.33%of the control group,the difference between two groups was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of TNF-α,IL-Iβand IL-6 between the two groups(P>0.05).After treatment,the levels of serum TNF-α,IL-Iβand IL-6 in two groups were lower than those before treatment,and the levels of cytokines in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions during treatment between two groups(P>0.05).Conclusion:Lamotrigine combined with Sodium Valproate is effective and safe in the treatment of newly diagnosed epilepsy.It is worthy of reference in clinical treatment.